The drug is the same one that Sir Bradley Wiggins received therapeutic use exemptions for in the build up to three grand tours between 2011 and 2013, including his victory in the 2012 Tour de France. He was allowed the TUEs as he needed the drug to prevent a flare-up of pollen-related breathing problems.